Jens Bedke

28PUBLICATIONS
79CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersSurface water quality processes and contaminated sediment assessmentMedical bacteriology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|May 16, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

|Feb 18, 2026
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr

|Dec 10, 2025
Disitamab Vedotin plus Toripalimab - New Players in Urothelial Carcinoma.

Jens Bedke

|Jan 20, 2024
Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma.

Viktoria Stühler, Bilal Alemi, Steffen Rausch

|Jan 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Robert J Motzer, Camillo Porta, Masatoshi Eto

|Mar 29, 2023
Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.

Moritz Maas, Aymone Kurcz, Jörg Hennenlotter

Pageof 5

Frequent Collaborators

4 joint publications

Steffen Rausch

4 joint publications

Arnulf Stenzl

2 joint publications

Thomas Powles

2 joint publications

Moritz Maas